Trials / Completed
CompletedNCT05511740
Circadian as A Prognostic Factor For Radiation Response in Cervical Cancer
Influence of Radiation Patterns Following Circadian Rhythm Upon Response of Radiotherapy of Uterine Cervical Cancer : Melatonin as a Radiosensitivity and Biological Marker
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- Indonesia University · Academic / Other
- Sex
- All
- Age
- 25 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The study was a Randomized Clinical Trial (RCT) or clinical trial comparing the results of radiation treatment of 2 treatment groups, i.e. subject groups irradiated in the morning and in the afternoon, to check melatonin levels in cervical cancer patients. Since it is known that the function of melatonin is as an antiproliferation substance or hormone, induces apoptosis, inhibits invasion and metastasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Afternoon Radiation | Melatonin, a hormone of the pineal gland, which levels are characteristic of circadian patterns, regulated with low levels of excretion in the afternoon, rises gradually during the night, peaks at dawn, and falls back in the afternoon and late afternoon. Many studies prove the function and potential of melatonin as circadian biomarkers and well correlated with the development of cancer.The function of melatonin is as an antiproliferation substance or hormone, induces apoptosis, inhibits invasion and metastasis. |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2014-07-01
- Completion
- 2014-07-01
- First posted
- 2022-08-23
- Last updated
- 2022-08-23
Source: ClinicalTrials.gov record NCT05511740. Inclusion in this directory is not an endorsement.